Where Patients Drop Out of the Clinical Trial Journey

Patient dropout is rarely caused by a single event. More often, participants disengage when the cumulative burden of a clinical trial becomes greater than the perceived value of continuing.

Travel to sites, complicated protocols, long waiting periods, repetitive assessments, unclear communication, technology friction, financial pressures, and lack of meaningful engagement can all weaken retention.

For sponsors and CROs, improving clinical trial retention starts with identifying where the patient journey breaks down—and designing systems and processes that reduce friction before participants disappear.

The Clinical Trial Doesn't End When a Patient Enrolls

Recruitment gets most of the attention in clinical trial planning.

Sponsors invest heavily in identifying eligible participants, accelerating screening, and filling sites. But enrollment is only the beginning.

The more difficult question is:

What happens after the patient says yes?

A participant may successfully complete screening, sign informed consent, receive the investigational product, and still eventually withdraw from the study.

That makes patient retention a journey rather than a single metric.

The U.S. Department of Health and Human Services identifies factors such as exclusion criteria, site proximity, out-of-pocket expenses, and patient and provider awareness as barriers to clinical trial participation.

And increasingly, researchers and regulators are recognizing that patient burden needs to be considered throughout trial design—not simply after retention problems appear.

The FDA's patient-focused drug development work specifically notes that failure to address burden or fatigue can contribute to missing data, poorer-quality data, and increased dropout.

So where does the journey actually start to break?

1. The First Drop-Off: Before Screening

Common friction points include:

• Difficulty understanding the study
• Lack of awareness about trial opportunities
• Complex eligibility requirements
• Fear or uncertainty about participation
• Distance from the clinical trial site
• Concerns about costs
• Lack of transportation
• Work or family responsibilities
• Limited communication with healthcare providers

A patient may be interested in participating but conclude that the practical cost is too high.

This is particularly important when trials require frequent site visits or involve populations with significant comorbidities.

The lesson: Recruitment should not only ask, "Can we find this patient?"

It should also ask:

"Can this patient realistically complete the protocol?"

2. Screening: When Complexity Starts to Show

Screening is often the patient's first significant interaction with the operational reality of a clinical trial.

What looked straightforward during recruitment can suddenly become complicated.

Patients may encounter:

• Multiple appointments
• Additional laboratory tests
• Medical records requests
• Questionnaires
• Eligibility assessments
• Waiting periods
• Repeated explanations
• Uncertainty about whether they have qualified

This creates an important psychological transition.

The patient moves from:

"I might participate in a clinical trial."

to:

"I have to do all of this to participate in a clinical trial."

That difference matters.

A trial may be scientifically necessary, but every additional procedure, visit, questionnaire, or technology requirement adds to the participant experience.

3. Informed Consent: The First Major Commitment Point

Informed consent is a critical ethical and regulatory process, but it is also an important patient-experience moment.

Participants need to understand:

• What will happen during the study
• How frequently they need to visit the site
• What procedures are involved
• Potential risks and discomforts
• Their responsibilities
• How their information will be used
• What happens if they withdraw

If expectations are unclear at this stage, dissatisfaction can appear later.

The goal isn't simply to obtain a signature.

It is to create a participant who understands what the journey actually looks like.

This is one reason patient engagement during trial design is increasingly emphasized. FDA guidance recognizes that incorporating patient perspectives into clinical study design and conduct can help address common challenges in clinical research.

4. The First Few Visits: Reality vs. Expectation

This is where the gap between what patients expected and what the trial requires can become obvious.

Imagine a participant who expected:

One visit, one treatment, and periodic follow-up.

Instead, they encounter:

• Long waiting times
• Multiple procedures
• Repeated questionnaires
• Blood draws
• Imaging
• Medication administration
• Device setup
• Electronic diaries
• Follow-up calls
• Additional site visits

None of these activities may seem unreasonable individually.

But together, they create participant burden.

And burden is cumulative.

A clinical trial that feels manageable during Week 1 can become exhausting by Month 3.

5. The "Middle of the Trial" Drop-Off

One of the most important retention risks is the middle of the study.

The initial motivation has started to fade.

The novelty is gone.

The participant has already completed several visits.

And the next visit may look almost identical to the previous one.

This is where clinical trial fatigue can emerge.

Participants may begin asking:

"How much longer do I have to do this?"

"Is this really helping me?"

"Why do I need to complete this questionnaire again?"

"Do I really need to travel to the site for this?"

These questions don't necessarily indicate dissatisfaction with the investigators or treatment.

They can indicate that the effort-to-value equation is changing.

Research on patient engagement has found that convenience-enhancing solutions are associated with higher trial satisfaction and perceptions of care and attention.

6. Technology Can Reduce Burden—or Create It

Digital transformation has created powerful opportunities to make clinical trials more patient-centric.

eConsent can simplify consent workflows.

ePRO can enable patients to report outcomes remotely.

Wearables can capture data continuously.

Telehealth can reduce unnecessary site visits.

Remote data collection can make participation more flexible.

But technology is not automatically synonymous with convenience.

A participant may now have to manage:

• A smartphone application
• Multiple passwords
• Wearable devices
• Bluetooth connections
• Notifications
• Daily questionnaires
• Device charging
• Technical support

Suddenly, the "digital clinical trial" can become another source of work.

Research into decentralized clinical trials has found that participants can perceive technology requirements as burdensome even when the actual daily time commitment is relatively small.

The objective should therefore be:

Technology that removes friction—not technology that moves friction onto the patient.

7. The Site Visit Becomes the Breaking Point

For many participants, the site remains one of the biggest sources of trial burden.

Consider the complete journey:

Home → transportation → traffic → parking → waiting room → procedures → consultation → paperwork → pharmacy → travel home

Now multiply that by 10, 20, or even 30 visits.

The clinical team may view each appointment as a necessary protocol activity.

The participant experiences it as a recurring interruption to everyday life.

Travel and scheduling challenges can become particularly significant for participants who have jobs, children, caregiving responsibilities, mobility limitations, or limited financial resources.

This is why decentralized and hybrid trial approaches can be valuable when appropriate. Digital and remote approaches can provide greater flexibility and allow some activities to happen outside the traditional site environment.

8. Communication Gaps: When Patients Feel Forgotten

A patient can be perfectly adherent and still become disengaged.

One reason is communication.

Participants may wonder:

• When is my next appointment?
• Did my results come back?
• Who should I contact with a question?
• Is this symptom expected?
• What happens next?
• Why haven't I heard from the study team?

Silence creates uncertainty.

And uncertainty can erode trust.

Retention is therefore not just about reminders.

It is about maintaining a relationship between the participant and the study team.

NIH-supported recommendations have highlighted strategies such as periodic communication outside study visits, culturally appropriate follow-up, and accommodations for scheduling, travel, and dependent-care needs as potential components of retention strategies.

9. The Hidden Dropout: Data Becomes Incomplete Before the Patient Leaves

Patient dropout isn't always binary.

A participant can remain technically enrolled while becoming increasingly disengaged.

They may:

• Miss questionnaires
• Skip electronic diaries
• Delay reporting
• Miss appointments
• Become difficult to contact
• Provide incomplete information
• Reduce adherence

This creates a dangerous middle ground:

The patient hasn't withdrawn—but the data is deteriorating.

That means sponsors should not rely exclusively on final dropout rates.

Leading indicators can be equally important.

10. The Final Dropout: When the Burden Wins

Eventually, a participant may decide:

"I don't want to continue."

Sometimes the reason is clinical.

Sometimes it is an adverse event.

Sometimes the treatment isn't working.

But sometimes the reason is surprisingly ordinary:

• "I can't keep traveling."
• "I don't have time."
• "It's too difficult."
• "I can't keep using the app."
• "I have to go back to work."
• "I don't have anyone to take care of my children."
• "I don't understand why I still need to come in."
• "It's taking too much out of my day."

These aren't necessarily failures of patient motivation.

They can be failures of trial design and participant experience.

What Sponsors Can Do to Reduce Clinical Trial Dropout

Improving retention doesn't begin after dropout rates increase.

It begins during protocol design.

1. Map the Patient Journey

Before a trial starts, map every activity from recruitment through study completion.

Ask:

What does the participant have to do?

Then ask:

What can we remove, simplify, combine, automate, or perform remotely?

Patient journey mapping can expose friction that isn't obvious when looking at individual protocol activities.

2. Measure Participant Burden

Don't measure only operational KPIs.

Track patient-experience indicators too.

Consider monitoring:

• Number of visits per participant
• Average visit duration
• Travel requirements
• Questionnaire frequency
• Device interactions
• Missed appointments
• ePRO completion rates
• Communication response rates
• Participant satisfaction
• Withdrawal reasons

The objective is to identify friction before attrition.

3. Use Digital Tools Strategically

Technology can make participation easier when it is thoughtfully implemented.

Depending on the protocol, sponsors can consider:

• eConsent
• ePRO
• Telehealth
• Remote patient monitoring
• Electronic diaries
• Automated reminders
• Patient portals
• Digital communication
• Remote data collection

But every technology decision should pass one test:

Does this make the patient's life easier?

If the answer is no, digitization may simply be transferring administrative work from the site to the participant.

4. Build Better Communication Loops

Patients shouldn't have to chase study teams for basic information.

Automated, personalized communication can help participants understand:

• Upcoming visits
• Required activities
• Reminders
• Study milestones
• Available support
• Who to contact

The technology should support—not replace—the human relationship between patients and study teams.

5. Design for Real Life

Clinical trial participants don't stop having lives because they join a study.

Protocols should account for:

• Work schedules
• Family responsibilities
• Transportation
• Geography
• Technology access
• Language
• Health literacy
• Accessibility
• Financial burden

Clinical research becomes more inclusive when the protocol is designed around real-world patient circumstances rather than assuming every participant has the same resources.

From Patient Retention to Patient-Centered Trial Design

The biggest shift is conceptual.

Instead of asking:

"How do we prevent patients from dropping out?"

Sponsors should ask:

"Why would a patient want to stay?"

That changes the approach.

Retention becomes less about repeatedly reminding participants to comply and more about designing a trial that is understandable, convenient, responsive, and respectful of their time.

Research on clinical trial digitization suggests that technology can improve recruitment and retention, but also warns that downstream retention challenges can emerge when digital approaches create additional burden.

The solution isn't necessarily a fully decentralized trial.

It may be a hybrid patient journey in which technology is used where it genuinely improves convenience, while human interaction remains available where it matters.

How Clinical Trial Technology Can Support Retention

A connected clinical trial ecosystem can help sponsors and CROs see more than isolated operational events.

Instead of viewing:

EDC → CTMS → ePRO → IWRS/RTSM → eConsent → eTMF

as separate systems, teams can increasingly think about the study as one connected operational environment.

That can help study teams understand:

• Where participants are in the journey
• Which visits are upcoming
• Where adherence is declining
• Which sites are experiencing operational friction
• Which participants may need additional support
• Where protocol activities are creating unnecessary burden

This is where integrated clinical trial technology becomes particularly valuable.

The goal isn't simply to collect more data.

It's to turn study data into earlier visibility—and earlier visibility into action.

The Patient Journey Is the Trial

Every clinical trial has two journeys.

The first is the operational journey:

Site → Sponsor → CRO → Data → Milestones → Submission

The second is the patient journey:

Awareness → Screening → Consent → Enrollment → Treatment → Follow-up → Completion

A trial can be operationally sophisticated while still being difficult for patients to navigate.

And when patients leave, the consequences extend beyond retention.

Dropout can contribute to missing data, increase recruitment pressure, disrupt timelines, and potentially affect the interpretability of study results. FDA guidance also makes clear that data already accrued from participants who withdraw remains part of the study record, underscoring the importance of planning for withdrawal and preserving appropriate data.

The strongest clinical trials therefore don't wait for patients to disengage.

They identify friction points early.

They simplify wherever possible.

They communicate consistently.

And they use technology to make participation easier—not merely more digital.

Final Takeaway

Patients don't usually drop out at one point in the clinical trial journey. They drop out at the point where cumulative friction becomes greater than their willingness or ability to continue.

That friction can begin before screening and increase through every visit, questionnaire, procedure, technology interaction, communication gap, and logistical challenge.

For sponsors and CROs, the opportunity is to stop treating retention as a downstream problem.

Patient retention should be designed into the trial from the beginning.

Because the most patient-centric clinical trial isn't necessarily the one with the most technology.

It's the one that asks, at every step:

"How can we make this easier for the person participating?"

How Octalsoft Helps

Octalsoft's connected eClinical ecosystem helps sponsors, CROs, and clinical research teams manage critical trial processes across platforms including CTMS, EDC, IWRS/RTSM, ePRO, eConsent, eTMF, eDOCS, rSDV, Imaging, and Clinical Analytics.

By connecting study operations and data workflows, clinical teams can gain greater visibility into trial execution, identify operational friction earlier, and build more efficient, participant-focused study processes.

Want to make your next clinical trial more connected and patient-centric? Talk to Octalsoft about building a smarter clinical trial ecosystem.